HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

Income Statement

Follow revenue through to earnings.

Revenue

$56.47M

FY 2025 · Annual

-0.3% YoY

Operating Income

-$4.18M

FY 2025 · Annual

Net Income

-$12.65M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.01M61.47M63.07M56.62M56.47M
Cost of Revenue3.97M4.98M7.62M9M32.46M
Gross Profit56.04M56.49M55.45M47.62M24.01M
Gross Margin93.4%91.9%87.9%84.1%42.5%
Research & Development00000
Selling, General & Admin32.06M35.58M28.29M26.93M22M
Operating Expenses62.32M69.98M55.45M55.31M28.19M
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
EBITDA25.41M18M12.88M17.22M18.02M
EBITDA Margin42.3%29.3%20.4%30.4%31.9%
Operating Income(6.24M)(13.44M)(10.35M)(7.69M)(4.18M)
Operating Margin-10.4%-21.9%-16.4%-13.6%-7.4%
Interest Income44K57K350K319K108.87K
Interest Expense6.96M7.32M8.75M10.08M7.22M
Other Income / Expenses(5.52M)(10.23M)(17.45M)(7.9M)(8.92M)
Income Before Tax(11.81M)(23.72M)(27.8M)(15.58M)(13.1M)
Pre-Tax Margin-19.7%-38.6%-44.1%-27.5%-23.2%
Income Tax Expense1.31M(124K)(272K)4.07M(452.79K)
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.65M)
Net Margin-21.9%-38.4%-43.6%-34.7%-22.4%
EPS (Basic)(0.41)(0.73)(0.85)(0.62)(0.40)
EPS (Diluted)(0.41)(0.73)(0.85)(0.62)(0.40)
Weighted Avg Shares32.18M32.33M32.26M31.84M31.53M
Weighted Avg Shares (Diluted)32.18M32.43M32.26M31.84M31.53M

HLS.TO Earnings Waterfall · TTM

TSX:HLS.TO · Revenue to Net Income

Key Ratios

EPS$-0.32
Gross Margin61.6%
Net Margin-18.7%
P/E Ratio-12.4
P/S Ratio8.1

Analysis

$55.8M of revenue converted into -$10.3M of net income for the selected period. Gross margin is 61.6% and net margin is -18.7%, showing how much revenue survives after costs and taxes. EPS is $-0.32, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

No filings found.

How much revenue does HLS.TO generate?

HLS Therapeutics Inc. (HLS.TO) reported $56.47M of revenue in fiscal 2025.

Is HLS.TO profitable?

HLS Therapeutics Inc. (HLS.TO) reported -$12.65M of net income, with a net margin of -22.4%.